|
|
 |
|
Trimeris, Inc. ("Trimeris") maintains this site (the "Site") for the user's personal entertainment, information, education, and communication purposes. You may browse the Site at your convenience and leisure.
The Site and its content are designed to comply with US laws and regulations. We intend the Site and its content to be accessed and used by US residents only, however, we recognize that the Site may be accessible by others.
The Site contains information about Trimeris and products, which are not presently approved or cleared by any government regulatory body for sale or use in any indication. Nothing contained on the Site should be construed as investment advice or as a solicitation or promotion for any product or for the use of any product in a particular way Specific questions about the products described on the Site should be directed to Trimeris via email or phone: (919) 806-4682. Further, nothing contained on the Site is intended to offer investment advice or medical advice for the treatment of illness or disease. Specific questions pertaining to the user's medical condition and appropriate treatment should be directed to the user's physician and/or other medical professional.
The Site contains information concerning Trimeris that may be useful or informative to our customers, employees, and stockholders, as well as the general public. Trimeris makes no representations or warranties as to the accuracy of any information contained on the Site. Trimeris expressly disclaims any obligation or duty to update or correct information contained on the Site. Trimeris assumes no liability or responsibility for any errors or omissions for the content of the Site.
This Site contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements provide Trimeris' current expectations or forecasts of future events. Generally, you can identify these statements by the fact that they use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning. While we believe these statements are accurate, our business is dependent on many factors, which include, but are not limited to: that we are a development-stage company that has sustained operating losses since our inception, and we expect these losses to continue; that we may not receive regulatory approvals for our drug candidates or approvals may be delayed; that we are dependent on the successful outcome of clinical trials for our drug candidates; that obtaining regulatory approvals and maintaining compliance with government regulations will entail significant costs that could harm our ability to achieve profitability; that our business is based on a novel technology called fusion inhibition, and unexpected side effects or other characteristics of this technology may delay or otherwise adversely affect the development, regulatory approval, and/or commercialization of our drug candidates; that failure to raise additional capital necessary to support our development programs and expand our operations could lower our revenues and reduce our ability to compete; that if sufficient amounts of our drug candidates cannot be manufactured on a cost-effective basis, our financial condition and results of operations will be materially and adversely affected; that if we cannot maintain commercial manufacturing arrangements with third parties on acceptable terms, or if these third parties do not perform as agreed, the commercial development of our drug candidates could be delayed or otherwise materially and adversely affected; that if we or our manufacturing partners do not maintain good manufacturing practices, it could negatively impact our ability to obtain regulatory approvals and commercialize our drug candidates; that if Roche does not meet its contractual obligations to us, our research and development efforts, and the regulatory approval and commercialization of our drug candidates could be delayed or otherwise materially and adversely affected; that our drugs may not achieve market acceptance; that even if we are successful in developing a commercially viable drug, in order to become profitable we will need to maintain arrangements with third parties for the sale, marketing, and distribution of our drug candidates or expend significant resources to develop these capabilities; that our internal research programs and our efforts to obtain rights to new products from third parties may not yield potential products for clinical development, which would adversely affect any future revenues; that we depend on patents and proprietary rights, which may offer only limited exclusive protection and do not protect against infringement; that if we are unable to protect our patents and proprietary rights, our assets and business could be materially harmed; that the intellectual property of our competitors or other third parties may prevent us from developing or commercializing our drug candidates; that we face intense competition in our efforts to develop commercially successful drugs in the biopharmaceutical industry; that if we are unable to compete successfully, our business will suffer; that uncertainty relating to third-party reimbursement and healthcare reform measures could limit the amount we will be able to charge for our drugs and adversely affect our results of operations; that if an accident or injury involving hazardous materials occurs, we could incur fines or liability, which could materially and adversely affect our business and our reputation; that if the testing or use of our drug candidates harms people, we could face costly and damaging product liability claims far in excess of our liability and indemnification coverage; that we are in litigation with a former consultant regarding compensation for services rendered; that our quarterly operating results are subject to fluctuations; that if our operating results for a particular period deviate from the levels expected by securities analysts and investors, it could adversely affect the market price of our common stock; that if we lose any of our executive management or other key employees, we will have difficulty replacing them; that if we cannot attract and retain qualified personnel on acceptable terms, the development of our drug candidates and our financial position may suffer; that any additional financing we obtain may result in dilution to our stockholders, restrictions on our operating flexibility, or the transfer of particular rights to technologies or drug candidates; that our bylaws require us to indemnify our officers and directors to the fullest extent permitted by law, which obligates us to make substantial payments and to incur significant insurance-related expenses. Many of these factors are beyond our control and any of these and other factors could cause actual results to differ materially from the forward-looking statements made in this Site. The results of our previous clinical trials are not necessarily indicative of the results of future clinical trials. We undertake no obligation to release publicly, the results of any revisions to the statements contained in this Site to reflect events or circumstances that occur subsequent to the date hereof. When you access and use the Site, you accept, without limitation or qualification, and agree to abide by the terms and conditions set forth in the Terms of Use.
|
|
|
|
 |
| Science can provide an answer, but the medicine provides new hope. |
|
 |
|
|
|